TITLE

Salmeterol/fluticasone of value for mild-to-moderate asthma

PUB. DATE
July 2007
SOURCE
PharmacoEconomics & Outcomes News;7/14/2007, Issue 532, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents a study on salmeterol/fluticasone for treatment of mild to moderate asthma. According to the research, the most cost effective first-line controller therapy in mild to moderate asthma is salmeterol/fluticasone propionate compared to fluticasone inhaled corticosteroids (FPIC), nonfluticasone propionate inhaled corticosteroids (nFPIC) and leukotriene modifiers (LMs). The likelihoood of salmeterol/fluticasone, nFPIC and LMs being cost-effective were 98% as revealed in a sensitivty analyses.
ACCESSION #
26001114

 

Related Articles

  • Salmeterol/fluticasone propionate: asthma-related QOL benefits.  // PharmacoEconomics & Outcomes News;5/16/2009, Issue 578, p10 

    The article discusses research on the use of salmeterol/fluticasone propionate delivered by hydrofluoroalkene metered dose inhaler (MDI) for asthma compared with its individual components and placebo delivered by chlorofluorocarbon MDI. It references a study by H. M. Edin et al published in the...

  • Which inhaler is best? Holmes, Bill // Journal of the Royal Society of Medicine;Feb1989, Vol. 82 Issue 2, p64 

    The article compares the features of two kinds of asthma inhalers available in the market. Inhalers are considered as safer drug delivery device because they provide direct application of the drugs to the bronchial mucosa by inhalation. One of these inhalers called as metered dose aerosol...

  • Effects of two inhaled corticosteroid/long-acting beta-agonist combinations on small-airway dysfunction in mild asthmatics measured by impulse oscillometry. Diong, Bill; Singh, Kshitiz; Menendez, Rogelio // Journal of Asthma & Allergy;2013, Vol. 6, p109 

    Background: We previously showed that the long-acting beta agonist (LABA) salmeterol as inhalation powder or metered-dose inhaler improves lung-function parameters assessed by impulse oscillometry (IOS) in 2- to 5-year-old children with reversible-airway disease within 15 minutes. Objective: We...

  • Budesonide/Formoterol Pressurized Metered-Dose Inhaler. Lyseng-Williamson, Katherine A; Simpson, Dene // Drugs;2008, Vol. 68 Issue 11, p1855 

    â–´ The corticosteroid budesonide and the long-acting ß2-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI) for use in patients aged ≥12 years with asthma.â–´ In well designed 12-week clinical trials...

  • Budesonide/formoterol pressurized metered-dose inhaler: a guide to its use in asthma.  // Drugs & Therapy Perspectives;Nov2009, Vol. 25 Issue 11, p1 

    The corticosteroid budesonide and the long-acting β2-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI). The combination pMDI improves lung function, asthma control, asthma symptoms and asthma-related quality of life outcomes in patients...

  • Asthma therapy: there are guidelines, and then there is real life…. Corrigan, Chris J. // Primary Care Respiratory Journal;Mar2011, Vol. 20 Issue 1, p13 

    The author reflects on asthma management highlighting the results of a study by Alison Hardwell and colleagues concerning asthma therapy. Hardwell and colleagues reportedly found that most patients are using pressurised metered-dose inhaler (pMDI) correctly. He discusses five potential causes of...

  • Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Chrystyn, Henry; Price, David // Primary Care Respiratory Journal;Dec2009, Vol. 18 Issue 4, p243 

    National and international asthma guidelines stress that before making changes to patients' therapy their compliance and inhaler technique should be checked. This review addresses these issues and highlights the differences between inhalers in terms of inhaler technique, individual...

  • DULERA 100/5.  // Monthly Prescribing Reference;Aug2010, Vol. 26 Issue 8, pA.11 

    The article offers information on the Dulera 100/5 medicine from Merck & Co. Inc. It mentions that the medicinal drug is indicated to maintain treatment of asthma in patients who are not completely controlled by other types of asthma medications. It also says that Dulera is an oral metered-dose...

  • Sticking to the Program. Smith, Rich // RT: The Journal for Respiratory Care Practitioners;Jul2008, Vol. 21 Issue 7, p16 

    The article discusses the importance of keeping the asthma patients into the metered dose inhaler (MDI) program, the introduction of the new MDI which contains a more environment-friendly propellant hydroflouroalkane. According to the author, keeping patients into the program will coax...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics